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Cholinergic basal forebrain neurons (CBFN) expressing the low-af-
¢nity neurotrophin receptor p75 (p75NTR) were previously selec-
tively labeled in vivo with carbocyanine 3 (Cy3)-tagged anti-
p75NTR, but the applied192IgG-conjugates recognizedp75NTR only
in rat.The antibodyME 20.4 raised against humanp75NTR hadbeen
shown to cross-reactwith thereceptor inmonkey, raccoon, sheep,
cat, dog, pig andrabbit.Hence, for invivo labeling of rabbit CBFNin
the present study, ME 20.4 was £uorochromated with Cy3-N-hy-
droxysuccinimide ester and puri¢ed Cy3-ME 20.4 was injected
intracerebroventricularly. Two days post-injection, clusters of
Cy3-ME 20.4 were found in CBFN displaying choline acetyltrans-
ferase-immunoreactivity. Following photoconversion, electron
microscopy revealed £uorochromated antibodies in secondary
lysosomes. In conclusion,Cy3-ME 20.4 might become an appropri-
atemarker forCBFNin live and ¢xed tissues of variousmammalian
species. NeuroReport 13:1395^1398c 2002 Lippincott Williams &
Wilkins.
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INTRODUCTION
Severe damage to cholinergic neurons of the basal forebrain
(BFB) is a major neuropathological hallmark of Alzheimer’s
disease, and this has prompted investigations focused on
this brain region in various mammalian species [1].
Neuroanatomical studies have achieved the identification
of cholinergic nerve cells by the detection of their marker
enzyme choline acetyltransferase (ChAT, EC 3.2.1.6) as well
as of vesicular acetylcholine transporters. An additional
selective marker of cholinergic BFB neurons is the low-
affinity neurotrophin receptor p75 (p75NTR), as was demon-
strated in the rat [2], raccoon [3], monkey [4] and human [5].
Targeting of p75NTR led to the development of cholinergic
immunolesion models. In particular, the in vivo application
of antibodies directed against an extracellular epitope of rat
p75NTR and conjugated to the ribosome-inactivating toxin
saporin (192IgG-saporin) caused selective lesions of choli-
nergic projection neurons in the rat BFB [6].
A further derivative of 192IgG, namely its conjugate with
the red fluorochrome carbocyanine 3 (Cy3-192IgG), was
introduced as a tool for the selective labeling of rat
cholinergic, p75NTR-bearing neurons both in vivo [7,8] and
in vitro [9]. 192IgG-conjugates are commonly infused
intracerebroventricularly and bind to p75NTR on cholinergic
terminals, become internalized as ligand/receptor com-
plexes and are transported retrogradely to the perikarya of
cholinergic BFB neurons [6]. Internalized Cy3-192IgG
molecules form clusters in secondary lysosomes [8].
Whereas ribosome inactivation by saporin causes neuronal
death [6,10], Wu et al. [11] demonstrated that pre-labeling of
cholinergic neurons with Cy3-192IgG does not alter their
electrophysiological and pharmacological properties in ex
vivo brain slice preparations containing the medial septum/
diagonal band complex (MSDB). Concordantly, identifica-
tion of cholinergic nerve cells with Cy3-192IgG in brain
slices led to new insights in the synaptic organization of
neurons in the MSDB with implications for learning and
memory [11,12].
However, 192IgG conjugates recognize p75NTR only in the
rat precluding their application in other mammalian species
(e.g. monkeys) with a BFB chemoarchitecture resembling
that in humans [13]. In contrast, the monoclonal antibody
ME 20.4 raised against an extracellular epitope of the human
p75NTR [14] was demonstrated to cross-react with p75NTR
also in monkey, raccoon [3], rabbit, pig, dog and cat [15].
Accordingly, the ME 20.4-saporin conjugate was shown to
be a selective cholinotoxin in the common marmoset [16],
rhesus monkey [17], rabbit [18] and sheep [19].
To overcome the restriction of in vivo labeling in the rat,
the present study investigated whether Cy3-ME 20.4 can be
employed as a marker of living cholinergic neurons in a
wide range of mammalian species expressing analogues of
the human p75NTR. Encouraged by recent data on ME 20.4-
saporin-induced immunolesions of cholinergic cells and
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subsequent b-amyloid deposition in the rabbit brain [18], the
potential of Cy3-ME 20.4 as a label for cholinergic nerve
cells was exemplified in studies on BFB neurons of this
animal species.
MATERIALS AND METHODS
Preparation of Cy3-ME 20.4: Cy3-ME 20.4 was prepared
by coupling the antibody with a chemically activated ester
of Cy3 under reaction conditions proved to maintain the
antigen-binding properties of ME 20.4 [20]. Four hundred
micrograms of ME 20.4 (pure IgG; AB-N07, Advanced
Targeting Systems, San Diego, CA, USA) were reacted with
a monofunctional Cy3-N-hydroxysuccinimide ester (Anti-
body Cy3 Labeling Kit, Amersham Pharmacia Biotech,
Freiburg, Germany) according to the instruction of the
manufacturer at pH 9.3 for 1 h, but with doubled dye:pro-
tein ratio. Thereafter, the reaction mixture was dialyzed
against phosphate-buffered saline (3  4 h) and the con-
centration of Cy3-ME 20.4 was adjusted to approximately
0.5 mg/ml prior its use for intracerebroventricular (i.c.v.)
injections.
Surgical procedure: New Zealand white rabbits of either
sex (n¼ 5; 2.3–5.1 kg; 4–21 months of age) were used in this
study. The rabbits were anesthetized with a mixture of
ketamine (50 mg/kg; Exalgon, Merck, Hallbergmoos, Ger-
many) and xylazine (4 mg/kg; Rompun, Bayer AG, Lever-
kusen, Germany), and their heads were mounted in a
stereotaxic frame. Two animals received unilateral i.c.v.
injections, and three animals were injected bilaterally with
16ml Cy3-ME 20.4 at an infusion speed of 0.5 ml/min with a
Hamilton microsyringe (Hamilton, Bonaduz, Switzerland).
Injection co-ordinates were applied according to Beach et al.
[18] at AP¼ 0.0 mm, L¼ 2.2 mm and DV¼ 9.0/7.5 mm
relative to bregma. All efforts were made to minimize
animal suffering throughout the experiments including
administration of the analgetic Metamizol (150 mg/kg;
Berlosin, Berlin-Chemie, Germany) immediately after op-
eration. The antibiotic Enrofloxacin (10 mg/kg daily; Baytril,
Bayer AG) was given orally throughout the post-injection
period. The care and treatment of the animals were in
accordance with the European Communities Council Direc-
tive (86/609/EEC) and approved by the Laboratory Animal
Care and Use Committee of the University of Leipzig (TVV-
Nr.15/00).
Immunocytochemistry and electron microscopy: Two days
post-injection rabbits were transcardially perfused with 4%
paraformaldehyde containing either 0.5% glutardialdehyde
(three animals) or 0.1% glutardialdehyde (two animals) in
0.1 M phosphate-buffer (pH 7.4). Whole brains were
removed from the skulls, divided into fore- and hindbrain
regions and post-fixed overnight in 4% paraformaldehyde.
Two forebrains were coronally sectioned on a vibratome at
50mm and the remaining tissue was cryoprotected and cut
at 30 mm on a cryostat microtome. Sections spanning the
MSDB and the anterior subdivision of the nucleus basalis
magnocellularis were washed with Tris-buffered saline
(TBS, 0.1 M, pH 7.4), rinsed in distilled water, mounted,
air-dried and coverslipped with Entellan (in toluene; Merck,
Darmstadt, Germany).
To determine the specificity of in vivo labeling, Cy3-ME
20.4 pre-labeled sections were applied to the concomitant
immunolabeling of ChAT and the calcium-binding protein
calretinin. Non-specific binding sites for the immunorea-
gents were primarily blocked with 5% normal donkey
serum in 0.1 M Tris-buffered saline (TBS) containing 0.3%
Triton X-100 for 1 h. Subsequently, the sections were
incubated with a mixture of affinity-purified goat anti-
ChAT (1:25; AB144P, Chemicon International; Hofheim,
Germany) and rabbit anti-calretinin (1:300; AB149, Chemi-
con) diluted in the blocking solution for 16 h. Next,
rinsed sections were reacted with a cocktail of Cy2-tagged
donkey anti-goat IgG and Cy5-conjugated donkey anti-
rabbit IgG (20 mg/ml; Dianova, Hamburg, Germany) diluted
in TBS containing 2% bovine serum albumin for 1 h.
Omission of the primary antibodies in control experiments
led to the absence of any cellular Cy2- and Cy5-labeling.
After the cytochemical procedures the sections were rinsed,
mounted, air-dried and coverslipped in Entellan. Fluores-
cence microscopy was performed using an Axioplan
microscope (Zeiss, Oberkochen, Germany) and selected
sections were inspected with a Zeiss 510 confocal laser-
scanning microscope.
To quench the autofluorescence caused by lipophilic
lipofuscin-like compounds in sections from 21-month-old
rabbits, tissue was treated with Sudan Black B according to
Schnell et al. [21] but prior to the immunofluorescence
labeling of cholinergic neurons. All Sudan Black B-pre-
treated sections were embedded in glycerol/gelatin (Sigma,
Deisenhofen, Germany).
The subcellular distribution of Cy3-ME 20.4 was deter-
mined following photoconversion of Cy3-ME 20.4 into an
electron-dense reaction product applying oxygen-enriched
photoconversion in a closed conversion chamber as de-
scribed previously [8]. Specimens were analyzed with a
Zeiss 900 electron microscope.
RESULTS
Two days following the i.c.v. infusion of Cy3-ME 20.4 there
was strong punctate labeling in many cells of the MSDB
(Fig. 1) that became less intense in the nucleus basalis
magnocellularis. This staining pattern was observed irre-
spective of the concentration of glutardialdehyde in the
fixative. In comparison to rabbits unilaterally infused with
Cy2-ME 20.4, bilaterally injected animals appeared to
contain more in vivo-labeled nerve cells in both hemi-
spheres.
In vivo labeling of Cy3-ME 20.4 was exclusively found in
cholinergic neurons, as revealed by their immunoreactivity
for ChAT (Fig. 1a) and p75NTR (not shown). In contrast,
in vivo labeling was never observed in non-cholinergic,
calretinin-immunoreactive nerve cells (Fig. 1b) that are
known to be intermingled with cholinergic neurons in the
border zone of the medial and lateral septum [22] and in
magnocellular, parvalbumin-containing GABAergic BFB
neurons (not shown).
It is noteworthy that treatment of the sections from 21-
month-old rabbits with Sudan Black B quenched the
autofluorescence caused by lipophilic lipofuscin-like com-
pounds. Importantly, Sudan Black B treatment only slightly
diminished the intensity of in vivo labeling with hydrophilic
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Fig. 1. The confocal laser-scanningmicrograph (a) shows red punctate Cy3-ME 20.4 in vivo labeling in cholinergic neurons of the rabbit medial septum.
Selectivity of Cy3-ME 20.4 for cholinergic neurons was demonstrated by co-localizationwith choline acetyltransferase (ChAT) that appears green (Cy2).
(b) Merged carbocyanine triple £uorescence staining of Cy3-ME 20.4 (red clusters) and immunoreactivities for ChAT (Cy2, green) and calretinin (Cy5,
color-coded in blue) in the border zone between themedial and lateral septum con¢rmed the speci¢city of in vivo labeling for cholinergic neurons and its
absence in non-cholinergic, calretinin-containing nerve cells. Bar¼ 25mm.
Fig. 2. Electron micrographs of cholinergic neurons in the medial septum (a) and, at higher magni¢cation, in the diagonal band of Broca (b) following
photoconversion of internalized Cy3-ME 20.4.The in vivo label was predominantly present in secondary lysosomes (arrows) after two days of survival. In
comparison to thephotoconvertedmaterial, non-labeledprimary lysosomes (arrowheads) are di¡erent in their size, shape and electron density. Prior to
print, the brightness and contrast of the electron micrographic images were digitally adjusted and shading correction was performed to reduce the
e¡ects of uneven illumination. Bar¼ 500nm (a), 250 nm (b).
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Cy3 and of the subsequently performed Cy2-immunostain-
ing of cholinergic neurons.
Electron microscopic analysis elucidated that Cy3-ME
20.4 was predominantly located intracellularly in secondary
lysosomes (Fig. 2a,b).
DISCUSSION
The granular cellular labeling of neurons in the rabbit BFB
with i.c.v. applied Cy3-ME 20.4 resembled that of Cy3-192IgG
in the rat BFB [7]. A subpopulation of cholinergic neurons in
the MSDB was unlabeled by Cy3-ME 20.4 that also parallels
the incomplete Cy3-192IgG labeling in the rat [7,11]. Recently,
the counting of Cy3-192IgG-positive cells in the rat BFB
revealed a medial septumhorizontal limb of the diagonal
band44nucleus basalis magnocellularis gradient of labeling
efficacy [23]. An apparently similar gradient was observed
after the in vivo labeling with Cy3-ME 20.4; that, however,
remains to be quantified. Future studies should also elucidate
whether the in vivo labeling with Cy3-ME 20.4 is long-term
stable or undergoes gradual clearance from the neurons, as
was previously shown for Cy3-192IgG in the rat [8].
The predominant location of Cy3-ME 20.4 in secondary
lysosomes, as revealed by electron microscopy, is identical
to the ultrastructural localization of Cy3-192IgG in rat basal
forebrain neurons [8]. This finding also corresponds with
the observation that lysosomes are preferred targets for
internalized nerve growth factor [24], the natural ligand of
p75NTR, which might be mimicked by fluorochromated
antibodies raised against p75NTR.
Whereas the quenching of autofluorescence with Sudan
Black B in the present work hardly affected the intensity of
in vivo labeling and subsequent immunofluorescence stain-
ing, strong autofluorescence might interfere with the
identification of cholinergic neurons with Cy3-ME 20.4 in
live brain slices originating from aged animals.
Our present findings suggest the potential use of Cy3-ME
20.4 in future neuropharmacological studies targeting the
cholinergic system of higher mammals. Such investigations
are also emphasized by the accelerated gathering of
pharmacological data based on the in vivo labeling of rat
cholinergic basal forebrain neurons [11,12]. In particular,
these studies showed that muscarinic receptor antagonists
induce memory impairment due to a decrease of septo-
hippocampal GABA release, instead of the previously
assumed diminished hippocampal acetylcholine release,
and confirmed neuroanatomical data on collaterals of
cholinergic neurons contacting parvalbumin-immunoposi-
tive GABAergic neurons within the MSDB [25].
CONCLUSION
The high interspecies variability of the chemical nature,
structure and topography of the cholinergic components in
magnocellular BFB nuclei hampers the development of
general functional concepts based on investigations of only
one or a few animal species. Therefore, the use of ME
20.4-saporin conjugates both in primates [16,17] and in
sheep [19] suggests that Cy3-ME 20.4 might be successfully
employed also in primates and ungulates, and become a
useful cholinergic marker to determine morphological,
electrophysiological and pharmacological parameters of
cholinergic neurons under physiological or pathological
conditions.
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